Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
作者机构：Department of GastroenterologyHôpital AvicenneAP-HPSorbonne Paris NordBobigny 93000France INSERM U-987Pathophysiology and Clinical Pharmacology of PainAmbroise ParéHospitalBoulogne-Billancourt 92100France allée Léon GambettaClichy 92110France
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2022年第28卷第7期
页 面：732-744页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Irritable bowel syndrome Probiotics Bifidobacterium longum Quality of life Severity of illness index Abdominal pain
摘 要：BACKGROUND Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome(IBS)symptoms compared with placebo in double-blind randomized ***,few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose *** To assess the effect of *** 35624 on IBS severity and quality of life in a reallife *** From November 2018 to January 2020,278 patients with IBS(according to Rome IV criteria)were enrolled in a prospective,open-label,multicenter observational study by private practice gastroenterologists to received one capsule of *** 35624(10^(9) colony-forming units)per day for 30 *** in the study was independently proposed to patients during spontaneous *** severity(assessed by the IBS severity scoring system)and patient quality of life(assessed by the IBS quality of life questionnaire)were compared between the inclusion visit(baseline)and the visit at the end of 30 d of *** characteristics of patients were described at *** variables comparisons between inclusion and end-of-treatment visits were performed using the t-test and Kruskal-Wallis *** variables comparisons were performed using theχ^(2) *** total of 233 patients,with a mean age of 51.4 years and composed of 71.2%women,were included in the *** these patients,48.1%had moderate IBS and 46.4%had severe *** a 30-d treatment period with one *** 35624 capsule per day,a significant decrease in IBS severity was observed compared to baseline(mean±SD,IBS severity scoring system scores:208±104 vs 303±81,P0.001)and 57%of patients moved to lower severity categories or achieved *** quality of life of patients was also improved by the treatment(IBS Quality of Life questionnaire score:68.8±20.9 vs 60.2±20.5;P0.001)and 63.8%of patients were satisfied with the *** Thirty days of treatment with *** 35624
维普期刊数据库